drugset / Trial / NCT04708158
Novaferon for COVID-19 Treatment Trial (NCTT-005)
RandomizedParallel-groupDouble-blindTreatment
Summary
A multicenter, randomized, double-blind, placebo-controlled trial for hospitalized moderate COVID-19 patients
Timeline
- Start
- 2021-03-25
- Primary completion
- 2023-04-30
- Completion
- 2023-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Novaferon | Protein / enzyme biologic | 20 ug | Inhaled |